Publicaciones en colaboración con investigadores/as de University of Pittsburgh (3)

2022

  1. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268

2019

  1. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

    Cell, Vol. 176, Núm. 1-2, pp. 334-347.e12

2016

  1. Emerging opportunities and challenges in cancer immunotherapy

    Clinical Cancer Research, Vol. 22, Núm. 8, pp. 1845-1855